-+ 0.00%
-+ 0.00%
-+ 0.00%
Annovis Bio’s Phase 3 Alzheimer’s Trial Gets Second Safety Panel Recommendation to Continue Unchanged
Share
Listen to the news
Annovis Bio’s Phase 3 Alzheimer’s Trial Gets Second Safety Panel Recommendation to Continue Unchanged
  • Annovis Bio received a second positive independent safety-board recommendation to continue its Phase 3 DUET-AD trial of buntanetap without modification.
  • The recommendation covers the investigational once-daily pill for early Alzheimer's disease, following a review of safety data through September 22, 2026.
  • The six-month treatment period is expected to end December 31, 2026, with database lock scheduled for February 8, 2027.
  • Six-month topline results will be reported in March 2027, including symptomatic results and detailed safety outcomes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170800PRIMZONEFULLFEED9879111) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending